• Explore /
  • Poster
  • / First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.

Abstract Poster

Authors

null

David F. McDermott

Beth Israel Deaconess Medical Center, Boston, MA

David F. McDermott , Jae-Lyun Lee , Marek Ziobro , Rustem Airatovich Gafanov , Vsevolod Borisovich Matveev , Cristina Suárez , Frede Donskov , Frederic Pouliot , Boris Y. Alekseev , Pawel Wiechno , Piotr Tomczak , Miguel Angel Climent Duran , Sang Joon Shin , Rachel Kloss Silverman , Rodolfo F. Perini , Charles Schloss , Michael B. Atkins

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT02853344

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 546)

DOI

10.1200/JCO.2019.37.7_suppl.546

Abstract #

546

Poster Bd #

D7

Abstract Disclosures

Similar Posters

First Author: Jae-Lyun Lee

First Author: Scott S. Tykodi

First Author: Jae-Lyun Lee

First Author: ANA Maria Arance Fernandez